🇺🇸 FDA
Pipeline program

AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

20240031

Phase 1 other active

Quick answer

AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors for KRAS Altered Advanced or Metastatic Solid Tumors is a Phase 1 program (other) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
KRAS Altered Advanced or Metastatic Solid Tumors
Phase
Phase 1
Modality
other
Status
active

Clinical trials